Zoetis Provides Units for Use in Regenerative Drugs Therapies to its Rising Equine Portfolio | 2021-06-01 | Press Releases

PARSIPPANY, NJ , June 1, 2021 / PRNewswire / – Zoetis Inc., the world’s leading animal health company, announced that it will add Pro-Stride to its portfolio of horse care products ® APS, rest ® PRP and Centrate ® BMA, a range of devices used to treat injuries common in horses that can cause lameness.

Lameness in horses as a result of musculoskeletal pain, particularly osteoarthritis, is one of the main reasons for a veterinary examination 1 and can have a significant impact on the physical, economic and quality of life for both the horse and the owner. Health care for the horse’s joints is an increasingly important segment in equine medicine 2 .

These stable-side devices offer the opportunity to use the natural healing mechanisms of a horse to treat joint and soft tissue diseases. A great advantage of using these devices is the ease with which the horses’ blood or bone marrow is processed on the side of the stable, which allows immediate use within 15-20 minutes of centrifugation; there is no need for incubation or preparation off-site.

“A healthy horse means more time in the saddle. Zoetis is committed to delivering solutions you can rely on through continuous innovation across the grooming continuum,” said Jeannie Jeffery , Vice President, US Equine at Zoetis. “The addition of Pro-Stride APS, Restigen PRP and Centrate BMA expands our ability to provide equine veterinarians with additional options to improve joint and soft tissue care and is an exciting demonstration of our commitment to horse health and wellbeing.”

Pro-Stride APS, Restigen PRP and Centrate BMA complete the constantly growing Zoetis family of horse care products. Zoetis will exclusively sell these products to veterinarians through key sales partners. For more information, please call Zoetis Customer Service at 1-888-Zoetis1 (1-888-963-8471).

About Zoetis

As the world’s leading animal health company, Zoetis has a single goal: to benefit our world and humanity by promoting animal care. After nearly 70 years of innovative methods for predicting, preventing, detecting and treating animal diseases, Zoetis continues to serve those who raise and care for animals worldwide – from ranchers to veterinarians and keepers. The company’s leading portfolio and pipeline of drugs, vaccines, diagnostics and technologies make a difference in over 100 countries. In 2020 Zoetis achieved sales of $ 6.7 billion with ~ 11,300 employees. For more, visit www.zoetis.com .

1.

USDA. 2000. Lameness and laminitis in US horses. USDA: APHIS: VS, CEAH, National Animal Health Monitoring System. Fort Collins, CO. # N318.0400.

2.

Velloso Alvarez, A, et al., A Survey of Clinical Use of Non-steroidal Intraarticular Therapeutics by Equine Practitioners. Front Vet Sci, 2020

All trademarks are owned by Zoetis Services LLC or one of its affiliates or licensors, unless otherwise stated. © 2021 Zoetis Services LLC. All rights reserved. GEQ-00751

Media contacts :

Colleen Cosgrove

Zoetis

862-217-3250

Colleen.cosgrove@zoetis.com

Lauren Klingler Tynan

609-213-3414

lauren.klinglertynan@mslgroup.com

View original content: http://www.prnewswire.com/news-releases/zoetis-adds-devices-for-use-in-regenerative-medicine-therapies-to-its-growing-equine-portfolio-301303068.html

SOURCE Zoetis Inc.